FDA Approved: ABIRATERONE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Abiraterone acetate (ANDA 210686) from BluePoint Laboratories, authorizing the continued manufacturing/availability …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

SUPPL AP for ABIRATERONE (ABIRATERONE ACETATE)